Results from a long-term field experiment shed new light on how grasslands can be restored for nature, the environment, and ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61. ...

Please go ahead. Thank you. Good afternoon and welcome to Tempus' first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

Tempus AI Inc. TEM during the first quarter secured a multi-million dollar deal to build “the world’s largest foundation model for oncology.” “And this is big for a few reasons,” said ...

Tempus AI has signed a three-way deal with AstraZeneca and Pathos AI to construct a data-based oncology model that could ultimately be used to develop new cancer drugs. Tempus will use its “vast ...

Please go ahead. Thank you. Good afternoon. And welcome to Tempus’ first quarter 2025 conference call. This afternoon, Tempus released results for the quarter ended March 31, 2025. The press ...

The Chicago-based startup formed in 2020 by Tempus AI executives Ryan Fukushima and Eric Lefkofsky is using an artificial intelligence platform, PathOS, to develop drugs, primarily in the oncology ...

CEO Eric Lefkofsky highlighted a record quarter for Tempus, with quarterly revenue increasing 75.4% year-over-year to $255.7 million. Genomics revenue grew 89% year-over-year to $193.8 million ...

Tempus AI announces a multi-year collaboration with AstraZeneca and Pathos AI to build a multimodal foundation model in oncology. Tempus says the collaboration includes $200 million in data ...

To fully understand how grassland ecosystems respond to global changes in precipitation and nutrient enrichment, both nutrient interactions and changes in plant communities should be considered.